Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Once-weekly etanercept improves patient-reported outcomes in patients with mild-moderate psoriasis

A 12-week, randomized, double-blind, placebo-controlled study evaluated the quality of life (QoL) and patient-reported outcomes (PROs) in psoriasis patients receiving once-weekly etanercept 50 mg (n = 96) or placebo (n = 46).This was followed by a 12-week open-label extension in patients with moderate-severe psoriasis. QoL assessments comprised the Dermatology Life Quality Inventory (DLQI), the EuroQoL-5D (EQ-5D) and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. At week 12, statistical (P < 0.05) and clinical improvement was produced in the etanercept group on the DLQI and EQ-5D but not FACIT-F scales. After 24 weeks of etanercept, the mean DLQI score improved slightly while EQ-5D and FACIT-F scores were close to the population ...